nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

28.05.2018 | Original Article – Cancer Research

TIS21^/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

verfasst von: Santhoshkumar Sundaramoorthy, Preethi Devanand, Min Sook Ryu, Kye Yong Song, Dong Young Noh, In Kyoung Lim

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer growth. We propose here a novel mechanism of the tumor suppresser, TIS21^/BTG2, that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity.

Methods

Transduction of adenovirus carrying TIS21^/BTG2 gene and transfection of short interfering RNAs were employed to regulate TIS21^/BTG2 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21^/BTG2 in breast cancer cells. Open data and immunohistochemical analysis were performed to confirm the role of TIS21^/BTG2 expression in various human breast cancer tissues.

Results

We observed that TIS21^/BTG2 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1^S473, but not AKT2, phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. TIS21^/BTG2-induced pAKT^S473 required Rictor-bound mTOR kinase, indicating activation of mTORc2 by TIS21^/BTG2 gene. Additionally, the TIS21^/BTG2-induced pAKT^S473 could reduce expression of NFAT1 (nuclear factor of activated T cells) and its target genes, which regulate cancer microenvironment.

Conclusions

TIS21^/BTG2 significantly lost in the infiltrating ductal carcinoma, but it can inhibit cancer growth via the TIS21^/BTG2–tsc1/2–mTORc1–p70S6K axis and downregulate cancer progression via the TIS21^/BTG2–mTORc2–AKT1–NFAT1–PHLPP2 pathway.

Nur mit Berechtigung zugänglich

Arboleda MJ et al (2003) Overexpression of AKT2/protein kinase B beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63:196–206PubMed

Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274–277CrossRefPubMed

Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29–86. https://doi.org/10.1016/S0065-230X(05)94002-5 CrossRefPubMed

Chen H, Pan H, Qian Y, Zhou W, Liu X (2018) MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer 17:4. https://doi.org/10.1186/s12943-017-0754-0 CrossRefPubMedPubMedCentral

Choi JA, Lim IK (2013) TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells. J Cancer Res Clin Oncol 139:1657–1665. https://doi.org/10.1007/s00432-013-1484-3 CrossRefPubMed

Choi JA, Jung YS, Kim JY, Kim HM, Lim IK (2016) Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes. Oncogene 35:83–93. https://doi.org/10.1038/onc.2015.64 CrossRefPubMed

Devanand P et al (2014) Inhibition of bladder cancer invasion by Sp1-mediated BTG2 expression via inhibition of DNA methyltransferase 1. FEBS J 281:5581–5601. https://doi.org/10.1111/febs.13099 CrossRefPubMed

Devanand P et al (2018) Inhibition of TNFalpha-interacting protein alpha (Tipalpha)-associated gastric carcinogenesis by BTG2(/TIS21) via downregulating cytoplasmic nucleolin expression. Exp Mol Med 50:e449. https://doi.org/10.1038/emm.2017.281 CrossRefPubMedPubMedCentral

Farioli-Vecchioli S et al (2007) Inhibition of medulloblastoma tumorigenesis by the antiproliferative and pro-differentiative gene PC3. FASEB J 21:2215–2225. https://doi.org/10.1096/fj.06-7548com CrossRefPubMed

Feng J, Park J, Cron P, Hess D, Hemmings BA (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279:41189–41196. https://doi.org/10.1074/jbc.M406731200 CrossRefPubMed

Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD (2001) Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 22:1271–1279CrossRefPubMed

Frampton AE et al (2015) Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet 385(Suppl 1):S37. https://doi.org/10.1016/S0140-6736(15)60352-X CrossRefPubMed

Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18:13–24. https://doi.org/10.1016/j.molcel.2005.03.008 CrossRefPubMed

Guardavaccaro D et al (2000) Arrest of G (1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 20:1797–1815CrossRefPubMedPubMedCentral

Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725–731. https://doi.org/10.1007/s10549-009-0674-9 CrossRefPubMed

Hong AE, Ryu MS, Kim SJ, Hwang SY, Lim IK (2018) PPAR alpha-target gene expression requires TIS21(/BTG2) gene in liver of the C57BL/6 mice under fasting condition. Mol Cells 41:140–149. https://doi.org/10.14348/molcells.2018.2257 PubMedPubMedCentralCrossRef

Ikenoue T, Hong S, Inoki K (2009) Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol 452:165–180. https://doi.org/10.1016/S0076-6879(08)03611-2 CrossRefPubMed

Jiang WG et al (2005) Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 41:1628–1636. https://doi.org/10.1016/j.ejca.2005.03.023 CrossRefPubMed

Kannan K et al (2001) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20:2225–2234. https://doi.org/10.1038/sj.onc.1204319 CrossRefPubMed

Kaunisto A et al (2015) NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol 9:1140–1154. https://doi.org/10.1016/j.molonc.2015.02.004 CrossRefPubMedPubMedCentral

Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S (2004) Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 23:8310–8319. https://doi.org/10.1038/sj.onc.1208008 CrossRefPubMed

Kawakubo H et al (2006) Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 66:7075–7082. https://doi.org/10.1158/0008-5472.CAN-06-0379 CrossRefPubMed

Kim BC, Ryu MS, Oh SP, Lim IK (2008) TIS21/(BTG2) negatively regulates estradiol-stimulated expansion of hematopoietic stem cells by derepressing Akt phosphorylation and inhibiting mTOR signal transduction. Stem Cells 26:2339–2348. https://doi.org/10.1634/stemcells.2008-0327 CrossRefPubMed

Lim IK, Lee MS, Lee SH, Kim NK, Jou I, Seo JS, Park SC (1995) Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines. J Cancer Res Clin Oncol 121:279–284CrossRefPubMed

Lim IK, Lee MS, Ryu MS, Park TJ, Fujiki H, Eguchi H, Paik WK (1998) Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog 23:25–35CrossRefPubMed

Liu M et al (2009) Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 19:828–837. https://doi.org/10.1038/cr.2009.72 CrossRefPubMed

Ma CX et al (2016) A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22:2650–2658. https://doi.org/10.1158/1078-0432.CCR-15-2160 CrossRefPubMedPubMedCentral

Mancini M, Toker A (2009) NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9:810–820. https://doi.org/10.1038/nrc2735 CrossRefPubMedPubMedCentral

Manning BD, Toker A (2017) AKT/PKB signaling: navigating the network. Cell 169:381–405. https://doi.org/10.1016/j.cell.2017.04.001 CrossRefPubMedPubMedCentral

Maroulakou IG, Oemler W, Naber SP, Tsichlis PN (2007) Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67:167–177. https://doi.org/10.1158/0008-5472.CAN-06-3782 CrossRefPubMed

Matsuda S, Rouault J, Magaud J, Berthet C (2001) In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497:67–72CrossRefPubMed

Melamed J, Kernizan S, Walden PD (2002) Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 34:28–32. https://doi.org/10.1054/tice.2001.0220 CrossRefPubMed

Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM (2002) PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18:333–334CrossRefPubMed

Oki Y et al (2015) Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171:463–470. https://doi.org/10.1111/bjh.13603 CrossRefPubMedPubMedCentral

Park TJ et al (2008) TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47:1533–1543. https://doi.org/10.1002/hep.22212 CrossRefPubMed

Partovian C, Simons M (2004) Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 16:951–957. https://doi.org/10.1016/j.cellsig.2004.01.008 CrossRefPubMed

Persad S et al (2001) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276:27462–27469. https://doi.org/10.1074/jbc.M102940200 CrossRefPubMed

Powell E et al (2016) p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18:13. https://doi.org/10.1186/s13058-016-0673-9 CrossRefPubMedPubMedCentral

Rouault JP et al (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14:482–486. https://doi.org/10.1038/ng1296-482 CrossRefPubMed

Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E, Lim IK (2004) TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 299:159–170. https://doi.org/10.1016/j.yexcr.2004.05.014 CrossRefPubMed

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101. https://doi.org/10.1126/science.1106148 CrossRefPubMed

Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H (2004) Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 64:1632–1638CrossRefPubMed

Stupfler B, Birck C, Seraphin B, Mauxion F (2016) BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation. Nat Commun 7:10811. https://doi.org/10.1038/ncomms108 CrossRefPubMedPubMedCentral

Sundaramoorthy S, Ryu MS, Lim IK (2013) B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFkappaB pathways which enhances transcription of MnSOD by accelerating IkappaBalpha degradation in normal and cancer cells. Cell Commun Signal 11:69. https://doi.org/10.1186/1478-811X-11-69 CrossRefPubMedPubMedCentral

Tajima K et al (2015) SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nat Commun 6:8257. https://doi.org/10.1038/ncomms9257 CrossRefPubMedPubMedCentral

Takahashi F et al (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30:3084–3095. https://doi.org/10.1038/onc.2011.24 CrossRefPubMed

Treins C, Warne PH, Magnuson MA, Pende M, Downward J (2010) Rictor is a novel target of p70 S6 kinase-1. Oncogene 29:1003–1016. https://doi.org/10.1038/onc.2009.401 CrossRefPubMed

Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A (2005) Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20:539–550. https://doi.org/10.1016/j.molcel.2005.10.033 CrossRefPubMed

Yoeli-Lerner M, Chin YR, Hansen CK, Toker A (2009) Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 7:425–432. https://doi.org/10.1158/1541-7786.MCR-08-0342 CrossRefPubMedPubMedCentral

Yu Y, Dai M, Lu A, Yu E, Merlino G (2018) PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation. Oncogene. https://doi.org/10.1038/s41388-017-0061-7 CrossRefPubMedPubMedCentral

Titel: TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis
verfasst von: Santhoshkumar Sundaramoorthy
Preethi Devanand
Min Sook Ryu
Kye Yong Song
Dong Young Noh
In Kyoung Lim
Publikationsdatum: 28.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2677-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

TIS21^/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Emerging strategies in BRCA-positive pancreatic cancer

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma

Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations

Relationship between TNF-α −1031T/C gene polymorphism, plasma level of TNF-α, and risk of cachexia in head and neck cancer patients

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie